An undisclosed, private, US-based investment company will invest up to $15m in milestone related equity in Keddem, with Compugen maintaining a minority interest
Compugen, a Nasdaq-listed drugs developer, has sold a majority stake in its Keddem Bioscience subsidiary as part of a growth-equity round.
An undisclosed, private, US-based investment company will invest up to $15m in milestone related equity in Keddem, with Compugen maintaining a minority interest and certain future preferential access rights to utilize the Keddem technology with Compugen discovered drug targets.
The concept underlying the technology was initially conceived and developed within the chemistry division of Compugen. In 2004, the program…
